ArticleFrontiers in immunology2025
Next-generation cell lines for profiling different proteasome forms and their implications in cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Most intracellular proteins undergo degradation by proteasomes, which exist in constitutive, immune, and intermediate forms. The diversity arises from the presence of different catalytic β subunits incorporated into the 20S core particle. Constitutive proteasomes contain β1, β2 and β5 subunits, whereas immunoproteasomes integrate β1i, β2i and β5i proteins. Intermediate proteasomes comprise combinations of constitutive and immune subunits, but typically lack the β2i subunit. Distinct proteasome configurations have widespread impact on cellular metabolism, gene expression, immune signaling, stress adaptation and tumorigenesis. However, the biological functions of proteasome subtypes remain incompletely defined, underscoring the need for refined experimental systems to uncover their specific activities. Methods: Previously, we generated cancer cell lines expressing mCherry-tagged β5i subunit under the control of endogenous regulatory elements. Using CRISPR/Cas9 nickase technology, we further modified the genomes of the colon adenocarcinoma SW620B8-mCherry and cervical adenocarcinoma TZM-blB8-mCherry cells. In SW620B8-mCherryB5-GFP cells, the Results: Efficient integration of fluorescent protein-encoding sequences into target genomes provided robust expression and integration of chimeric subunits into proteasomes. In TZM-blB8-mCherryB10-CFP cells, photo-conversion of PS-CFP2 allowed visualization of both intermediate and immunoproteasomes within the cellular nuclei following treatment with IFN-γ/TNF. In SW620B8-mCherryB5-GFP cells, analysis of intracellular proteasome localization revealed discrete regions enriched in β5i-containing proteasomes. Moreover, IFN-γ/TNF exposure induced a fluorescence shift from green to red, accompanied by redistribution of intracellular proteasomes in SW620B8-mCherryB5-GFP cells. Multiphoton microscopy of tumors grafted into immunocompromised mice showed the formation of β5i-containing, proteasome-enriched inclusions and suggested their potential release from cancer cells. Collectively, the TZM-blB8-mCherryB10-CFP cell line provides a tool to interrogate immunoproteasome functions independently of intermediate proteasomes, whereas SW620B8-mCherryB5-GFP cells enable visual discrimination between constitutive and β5i-containing proteasomes both Conclusions: Generated cell lines provide a novel platform for dissecting proteasome functions, addressing the distinct properties of individual proteasome forms, and assessing the impact of diverse compounds on the proteasome repertoire in cultured cells and in tumor xenografts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.